Brief: Sesen Bio Reiterates Confidence That Pending Merger With Carisma Is In Best Interests Of Stockholders
26/01/2023 13:23
Jan 26 (Reuters) - Sesen Bio Inc SESN.O :
* SESEN BIO REITERATES CONFIDENCE THAT PENDING MERGER WITH
CARISMA
IS IN BEST INTERESTS OF STOCKHOLDERS
Source text for Eikon: ID:nBw328B8qa
Further company coverage: SESN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary